Loureirin B inhibits Cervical Cancer Development by Blocking PI3K/AKT Signaling Pathway: Network Pharmacology Analysis and Experimental Validation
Applied Biochemistry and Biotechnology · 2024
DOI: 10.1007/s12010-024-04975-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Biochemistry and Biotechnology, 2024. Verfasst von Yinwen Hong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Proto-Oncogene Proteins c-akt, Signal Transduction, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, China.
- Department of Colorectal Surgery, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, No.18, Yangsu Road, Suzhou, 215000, China. sunxueliang-2005@163.com.
- Department of Gynecology, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, No.18, Yangsu Road, Suzhou, 215000, China. lulijuanmary@163.com.
Zitieren
APA
Hong, Y., Sun, X., & Lu, L. (2024). Loureirin B inhibits Cervical Cancer Development by Blocking PI3K/AKT Signaling Pathway: Network Pharmacology Analysis and Experimental Validation. Applied Biochemistry and Biotechnology. https://doi.org/10.1007/s12010-024-04975-7
Vancouver
Hong Y, Sun X, Lu L. Loureirin B inhibits Cervical Cancer Development by Blocking PI3K/AKT Signaling Pathway: Network Pharmacology Analysis and Experimental Validation. Applied Biochemistry and Biotechnology. 2024. doi:10.1007/s12010-024-04975-7
BibTeX
@article{Hong2024,
author = {Hong, Yinwen and Sun, Xueliang and Lu, Lijuan},
title = {Loureirin B inhibits Cervical Cancer Development by Blocking PI3K/AKT Signaling Pathway: Network Pharmacology Analysis and Experimental Validation},
journal = {Applied Biochemistry and Biotechnology},
year = {2024},
doi = {10.1007/s12010-024-04975-7}
}
EUVIMED